You are here: Research » IBD » Canterbury IBD Project Publications
Print This Page

Canterbury IBD Project Publications

Journal Publications                                                                                                                   Meeting Abstracts

  1. Gearry RB, Barclay ML, Gardiner SJ, Zhang M, Harraway J, George P, Roberts RL, Kennedy MA, Pike L. 6-thioguanine nucleotides and thiopurine methyltransferase activity: important factors determining response to treatment and incidence of adverse effects from azathioprine and 6-MP. New Zealand Medical Journal. 2003;116(1178):U531 http://www.nzma.org.nz/journal/116-117/531/
  2. Gearry R B, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, Kennedy MA. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2003;18:395-400.
  3. Gearry RB, Carne PA, Frizelle FA. Takayasu’s Arteritis and Ulcerative Colitis. New Zealand Medical Journal. 2003;116 (1170):U359. http://www.nxma.org.nz/journal/116-1170/359/
  4. Keenan J. Gearry RB, Neal S. Non-pylori Helicobacter species in Gastrointestinal disease. New Zealand Medical Journal 2003; 116(1179):U546 http://www.nzma.org.nz/journal/116-1179/546/
  5. Gearry RB, Wakeman CJ, Barclay ML, Burt MJ, Chapman BA, Collett JA, Frizelle FA. A National Survey of Colonoscopic Surveillance for Dysplasia in Patients with Ulcerative Colitis. Dis Colon Rectum 2004; 47(3):314 – 322
  6. Roberts RL, Barclay ML, Gearry RB, Kennedy MA. A multiplexed allele-specific assay for the detection of thiopurine methyltransferase (TPMT) alleles Clin Chem Acta 2004;341:49-53
  7. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA.  Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2004;13:563-7
  8. Gearry RB, Roberts RL, Barclay ML, Kennedy MA. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine.. Pharmacogenetics 2004;14:779-781
  9. Sies C, Pike LS, Harraway J, Walmsley TY, Florkowski CM, George PM, Gearry RB, Barclay ML. Development of a radiochemical and genotyping service for TPMT activity. New Zealand Medical Journal 2005;118(1210):U1324. http://www.nzma.org.nz/journal/116-1178/1324/
  10. Gearry RB, Barclay ML, Florkowski CM, Walmsley TY George PM. Faecal Calprotectin: a better non-invasive means of assessing intestinal inflammation. New Zealand Medical Journal 2005;118(1214):U1444
  11. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring: a review of clinical use in inflammatory bowel disease. Journal of Gastroenterology and Hepatology 2005;20 (8): 1149-1157
  12. Roberts RL, Gearry RB, Barclay ML, Kennedy MA. Rapid detection of common CARD15 variants in patients with inflammatory bowel disease. Mol Diagn. 2004;8(2):101-5.
  13. Gearry RB, Barclay ML, Roberts RL, Harraway J, Zhang M, Pike LS, Florkowski CM, George PM. TPMT and 6-thioguanine nucleotide measurement: Early experience of use in clinical practice. Internal Medicine Journal 2005;35:580-585
  14. Gearry RB, Aitken JM, Roberts RL, Ismail S, Keenan J, Barclay ML. Mycobacterium avium paratuberculosis and Crohn's disease (Image of Interest) Journal of Gastroenterology and Hepatology 2005;20:1943
  15. Roberts RL, Gearry RB, Allington MDE, Morrin HR, Robinson BA, Frizelle FA. Caspase Recruitment Domain-Containing Protein 15 (CARD15) mutations in patients with colorectal cancer. Cancer Research, 2006;66(5):2532-5
  16. Gearry RB, Lea RA, Roberts RL, Chambers GK, Barclay ML, Kennedy MA. CARD15 allele frequency differences in New Zealand Maori: Ancestry-specific susceptibility to Crohn’s disease in New Zealand. Gut 2006;55:580
  17. Gardiner SJ, Gearry RB, Roberts RL, Zhang M, Barclay ML, Begg EJ. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. British Journal of Clinical Pharmacology 2006;62(4):473-476
  18. Gardiner SJ, Gearry RB, Barclay ML, Begg EJ. Two cases of TPMT deficiency – a lucky save and a near miss with azathioprine. British Journal of Clinical Pharmacology 2006;62(4):453-456
  19. Priest VL, Begg EJ, Gardiner SJ, Frampton CM, Barclay ML, Gearry RB, Clark DW.  Cost-effectiveness of azathioprine and methotrexate, and pharmacogenetic (TPMT) testing in inflammatory bowel disease.  Pharmacoeconomics Journal 2006;24(8):767-781
  20. Roberts RL, Gearry RB, Barclay ML, Kennedy MA. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. The Pharmacogenomics Journal E-Pub, 2006
  21. Gearry RB, Richardson A, Frampton CMA, Collett JA, Chapman BA, Burt MJ, Barclay ML. High incidence of Crohn’s disease in Canterbury, New Zealand - results of an epidemiological study. Inflammatory Bowel Diseases  2006;12(10); 936-943
  22. Browning BL, Huebner C, Petermann I, Gearry RB, Barclay ML, Shelling AN, Ferguson LR. Association of DLG5 variants with inflammatory bowel disease in the New Zealand Caucasian population and meta-analysis of the DLG5 R30Q variant. Inflammatory Bowel Diseases  (In Press)
  23. Browning BL, Huebner C, Petermann I, Gearry RB, Barclay ML, Shelling AN, Ferguson LR. Has toll-like receptor 4 been prematurely rejected as an inflammatory bowel disease gene?  Association study combined with meta-analysis shows strong evidence for association. American Journal of Gastroenterology (In Press)
  24. Roberts RL, Gearry RB, Barclay ML, Miller A, Reid J, Abkevich V, Timms KM, Gutin A,  Lanchbury JS, Merriman TR, Kennedy MA The IL23R gene is associated with inflammatory bowel disease in New Zealand Caucasians. American Journal of Gastroenterology (In Press)
  25. Gearry RB, Roberts RL, Burt MJ, Frampton CMA, Chapman BA, Collett JA, Shirley PM, Allington MD, Kennedy MA, Barclay ML. Effect of inflammatory bowel disease classification changes on NOD2 genotype-phenotype associations in a population-based cohort. Inflammatory Bowel Diseases (In Press)
  26. Gardiner SJ, Gearry RB, Roberts RL, Zhang M, Barclay ML, Begg EJ. Comment: Breast-feeding during maternal use of azathioprine. Annals of Pharmacotherapy 2007 (In Press)
  27. Browning BL, Barclay ML, Bingham SA, Brand S, Büning C, Castro M, Cucchiara S, Dallapiccola B, Drummond H, Ferguson LR, Ferraris A, Fisher SA, Gearry RB, Glas J, Henckaerts L, Huebner C, Knafelz D, Lakatos L, Lakatos PL, Latiano A, Liu X, Mathew C, Müller-Myhsok B, Newman WG, Nimmo ER, Noble CL, Palmieri O, Parkes M, Petermann I, Rutgeerts P, Satsangi J, Shelling AN,  Siminovitch KA, Török H-P, Tremelling M, Vermeire S, Valvano MR, Vito A, Witt H. Gender-stratified analysis of DLG5 R30Q in 4707 Crohn’s disease patients and 4973 controls from 12 Caucasian cohorts. Journal of Medical Genetics (In Press)

Meeting Abstracts

Barclay ML, Gearry RB, Burt MJ, Collett JA. Azathioprine and 6-mercaptopurine adverse effects and TPMT genotype in patients with inflammatory bowel disease.

  • Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, New Zealand Section Annual Meeting, Christchurch, New Zealand, 2002.
  • Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, New Zealand Section Annual Meeting, Melbourne, Australia, 2002.
  • New Zealand Society of Gastroenterology Annual Scientific Meeting, Wellington, 2001


Wakeman CJ, Gearry RB, Frizelle FA, Barclay ML, Chapman BA, Burt MJ, Collett JA. A National Survey of Colonoscopic Surveillance for Dysplasia in Patients with Ulcerative Colitis.

  • Royal Australasian College of Surgeons Annual Scientific Congress, Brisbane, Australia, 2003. ANZ J Surg 2003;73(Suppl):CR05.
  • New Zealand Society of Gastroenterology Annual Scientific Meeting, Auckland, 2002.


Gearry RB, Barclay ML, Burt MJ, Chapman BA, Collett JA, George, PM.Comparison of Faecal Calprotectin and Clinical Disease Indices for Assessing Inflammation in Crohn’s Disease.

  • New Zealand Society of Gastroenterology Annual Scientific Meeting, Queenstown, 2003 http://www.nzma.org.nz/journal/117-1195/916/


Gearry RB, Barclay ML, Frampton CMA, Richardson A, Dodshun AJ, Collett JA, Chapman BA, Burt, MJ, Interim results of a population-based case-control study assessing environmental risk factors for Crohn’s disease.

  • Canterbury Medical Research Society Annual Conference, Christchurch,  2004


Roberts RL, Gearry RB, Barclay ML, Kennedy MA.  Interim CARD15 genotyping results from a population-based study of inflammatory bowel disease.

  • European Society of Human Genetics Annual Meeting, Prague, Czech Republic, 2005
  • World Congress of Gastroenterology, Montreal, 2005


Gearry RB, Roberts RL, Richardson A, Frampton CAM, Kennedy MA, Barclay ML. The prevalence and genetic determinants of inflammatory bowel disease (IBD) in Canterbury.

  • Canterbury Health Science Research Conference, Christchurch, New Zealand, 2005


Barclay ML, Gearry RB, Frampton CMA, Richardson A, Dodgshun AJ. Increasing duration of breastfeeding is associated with a decreasing risk of Crohn’s disease in later life.

  • World Congress of Gastroenterology, Montreal, 2005


Gearry RB, Roberts RL, Richardson A, Frampton CAM, Kennedy MA, Barclay ML. The epidemiology and genetic determinants of inflammatory bowel disease (IBD) in Canterbury.

  • New Zealand Gastroenterological Society Annual Scientific Meeting, Hamilton, 2005


Barclay ML, Roberts RL, Gearry RB, Kennedy MA, Gardiner SJ, Dodgshun AJ. Breastfeeding and Crohn’s disease.

  • New Zealand Gastroenterological Society Annual Scientific Meeting, Hamilton, 2005


Gearry RB, Richardson A, Frampton CMA, Chapman BA, Burt MJ, Collett JA, Barclay ML. High rate of Crohn’s disease in Canterbury, New Zealand – results of a population-based study.

  •  Falk Symposium 151 – Emerging Issues in Inflammatory Bowel Diseases, Sydney, 2006


Gearry RB, Richardson A, Frampton CM, Collett JA, Dodgshun A, Chapman BA, Burt MJ, Barclay ML. Environmental factors associated with ulcerative colitis: a large population-based case-control study.

  • Gastroenterology 2006;130(4) Suppl 2: 901 Digestive Diseases Week, Los Angeles, 2006
  • Journal of Gastroenterology and Hepatology 2006 (Oct);21(4):A271 Australian Gastroenterology Week, Adelaide, 2006.


Gearry RB, Roberts RL, Frampton CM, Burt MJ, Collett JA, Chapman BA, Allington MD, Kennedy MA, Barclay ML. From Vienna to Montreal: the impact of changes in IBD classification on CARD15 genotype-phenotype relationships in a population-based cohort.

  • Gastroenterology 2006;130(4) Suppl 2: T1979. Digestive Diseases Week, Los Angeles, 2006
  • Journal of Gastroenterology and Hepatology 2006 (Oct);21(4):A271 Australian Gastroenterology Week, Adelaide, 2006.


Gearry RB, Richardson A, Frampton CM, Collett JA, Dodgshun A, Chapman BA, Burt MJ, Barclay ML. Environmental factors associated with Crohn's disease: a large population-based case-control study.

  • Gastroenterology 2006;130(4) Suppl 2: W1039. Digestive Diseases Week, Los Angeles, 2006
  • Journal of Gastroenterology and Hepatology 2006 (Oct);21(4):A270 Australian Gastroenterology Week, Adelaide, 2006.


Gearry RB, Richardson A, Frampton CM, Collett JA, Chapman BA, Burt MJ, Barclay ML. High rate of Crohn's disease in Canterbury, New Zealand - results of a population-based study.

  • Gastroenterology 2006;130(4) Suppl 2: W1044. Digestive Diseases Week, Los Angeles, 2006


Barclay ML, Ailabouni R, Gearry RB, Frampton C. Complementary and alternative medicine use in IBD is determined by age, sex and socioeconomic status and is no different than in controls without IBD.

  • Journal of Gastroenterology and Hepatology 2006 (Oct);21(4):A251, Australian Gastroenterology Week, Adelaide, 2006.


Barclay ML, Gardiner SJ, Gearry RB, Roberts RL, Zhang M, Begg EJ. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs.

  • Journal of Gastroenterology and Hepatology 2006 (Oct);21(4):A252 Australian Gastroenterology Week, Adelaide, 2006.


Gearry RB, Montgomery SM, Frampton CM, Barclay ML. A systematic review of case-control studies assessing environmental factors associated with inflammatory bowel disease (IBD)

  • Journal of Gastroenterology and Hepatology 2006 (Oct);21(4):A261 Australian Gastroenterology Week, Adelaide, 2006.


Gearry RB, Frampton CM, Collett JA, Chapman BA, Burt MJ, Shirley P, Barclay ML. Inflammatory Bowel Disease (IBD) related morbidity in a population-based cohort.

  • Journal of Gastroenterology and Hepatology 2006 (Oct);21(4):A274 Australian Gastroenterology Week, Adelaide, 2006.
  • Proceedings of the New Zealand Society of Gastroenterology Annual Scientific Meeting, Blenheim, November 2006.


Roberts RL, Gearry RB, Kennedy MA, Barclay ML. Mutations in the guanosine 5’ monophospate synthetase ((GMPS) gene are associated with thiopurine resistance.

  • New Zealand Medical Sciences Congress, 2006


Browning BL, Huebner C, Petermann I, Demmers P, McCulloch A, Gearry RB, Barclay ML, Shelling AN, Ferguson LR. Association of DLG5 variants with inflammatory bowel disease in the New Zealand Caucasian population and meta-analysis of the DLG5 R30Q variant.

  • New Zealand Medical Sciences Congress, 2006


Gardiner SJ, Gearry RB, Begg SJ, Barclay ML. Thiopurine Methyl Transferase (TPMT) and thiopurine dose in inflammatory bowel disease (IBD).

  • Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, Melbourne, Australia, 2006.



^ Top

Previous page: Inflammatory Bowel Disease Research
Next page: Bowel Cancer Research